Safe & secure Alnylam Pharmaceuticals Tokenized Stock (Reality) wallet
Take control of your Alnylam Pharmaceuticals Tokenized Stock (Reality) assets with complete confidence in the Trezor ecosystem.
- Secured by your hardware wallet
- Use with compatible hot wallets
- Trusted by over 2 million customers

Send & receive your Alnylam Pharmaceuticals Tokenized Stock (Reality) with the Trezor Suite app
Send & receive
Trezor hardware wallets that support Alnylam Pharmaceuticals Tokenized Stock (Reality)
Sync your Trezor with wallet apps
Supported Alnylam Pharmaceuticals Tokenized Stock (Reality) Network
Why a hardware wallet?
Go offline with Trezor
- You own 100% of your coins
- Your wallet is 100% safe offline
- Your data is 100% anonymous
- Your coins aren’t tied to any company
Online exchanges
- If an exchange fails, you lose your coins
- Exchanges are targets for hackers
- Your personal data may be exposed
- You don’t truly own your coins
How to RALNY on Trezor
Connect your Trezor
Open a third-party wallet app
Manage your assets
Make the most of your RALNY
Trezor keeps your RALNY secure
Protected by Secure ElementThe best defense against both online and offline threats
Your tokens, your controlAbsolute control of every transaction with on-device confirmation
Security starts with open-sourceTransparent wallet design makes your Trezor better and safer
Clear & simple wallet backupRecover access to your digital assets with a new backup standard
Confidence from day onePackaging & device security seals protect your Trezor’s integrity
Alnylam Pharmaceuticals, Inc. is a leading global biopharmaceutical company at the forefront of developing innovative RNA interference (RNAi) therapeutics. The company pioneered the translation of Nobel Prize-winning science into an entirely new class of innovative medicines. Utilizing its proprietary drug delivery technology platforms, Alnylam is dedicated to the R&D, manufacturing, and commercialization of breakthrough small interfering RNA (siRNA) medicines targeting rare diseases, cardiovascular conditions, metabolic disorders, and central nervous system diseases. As an industry pioneer, it possesses a strong core moat in the commercialization and pipeline expansion of gene-silencing technologies.
